SG10201913536TA - Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies - Google Patents

Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies

Info

Publication number
SG10201913536TA
SG10201913536TA SG10201913536TA SG10201913536TA SG10201913536TA SG 10201913536T A SG10201913536T A SG 10201913536TA SG 10201913536T A SG10201913536T A SG 10201913536TA SG 10201913536T A SG10201913536T A SG 10201913536TA SG 10201913536T A SG10201913536T A SG 10201913536TA
Authority
SG
Singapore
Prior art keywords
antibodies
bispecific antibodies
therapeutic use
manufacturing
bispecific
Prior art date
Application number
SG10201913536TA
Inventor
Michael Otto Bardroff
Tina Buch
Christian Graf
Daniel Heitmann
Thomas Jostock
Hans-Peter Knopf
Rolf Koehler
Jiri Kovarik
Stephen John Oliver
Dhavalkumar Patel
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201913536TA publication Critical patent/SG10201913536TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201913536TA 2017-06-12 2018-06-08 Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies SG10201913536TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762518090P 2017-06-12 2017-06-12

Publications (1)

Publication Number Publication Date
SG10201913536TA true SG10201913536TA (en) 2020-02-27

Family

ID=62948274

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201913536TA SG10201913536TA (en) 2017-06-12 2018-06-08 Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies

Country Status (25)

Country Link
US (2) US20190002589A1 (en)
EP (1) EP3638692A1 (en)
JP (2) JP7106234B2 (en)
KR (2) KR20200005746A (en)
CN (1) CN110730788A (en)
AR (1) AR112419A1 (en)
AU (2) AU2018284303B2 (en)
BR (1) BR112019025904A2 (en)
CA (1) CA3061097A1 (en)
CL (1) CL2019003613A1 (en)
CO (1) CO2019013838A2 (en)
CR (1) CR20190558A (en)
CU (1) CU20190100A7 (en)
EA (1) EA201992670A1 (en)
EC (1) ECSP19087580A (en)
IL (1) IL271179A (en)
JO (1) JOP20190283B1 (en)
MA (1) MA49394A (en)
MX (1) MX2019015021A (en)
PE (1) PE20200384A1 (en)
SG (1) SG10201913536TA (en)
TW (1) TWI826377B (en)
UY (1) UY37758A (en)
WO (1) WO2018229612A1 (en)
ZA (1) ZA201906757B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
JOP20200308A1 (en) * 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CN110658340B (en) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 Bispecific antibodies or antibody mixtures with a common light chain
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CN116396393A (en) 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 Antigen binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. Acoustic transducer drive and controller
CA3098277A1 (en) * 2018-05-09 2019-11-14 Novartis Ag Use of canakinumab
CN111018969A (en) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 Method for purifying bispecific antibody by light chain select combined chromatography
WO2021170060A1 (en) * 2020-02-28 2021-09-02 Wuxi Biologics (Shanghai) Co., Ltd. Purification of bispeciifc antibodies
WO2022098628A2 (en) * 2020-11-04 2022-05-12 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
CA3201637A1 (en) * 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
KR20240023123A (en) 2021-06-22 2024-02-20 노파르티스 아게 Bispecific antibodies for use in the treatment of hidradenitis suppurativa
CN113980135B (en) * 2021-12-27 2022-04-19 三优生物医药(上海)有限公司 Anti-drug antibody combined with coronavirus bispecific antibody, preparation method and application thereof
TW202400658A (en) * 2022-04-26 2024-01-01 瑞士商諾華公司 Multispecific antibodies targeting il-13 and il-18

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
HU215180B (en) 1992-01-23 1998-10-28 Merck Patent Gmbh. Process for production of monomeric and dimeric antibody-fragment fusion proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20030148463A1 (en) * 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
AU7684201A (en) 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
PL2848258T3 (en) 2005-10-26 2018-06-29 Novartis Ag Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
WO2007120828A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
EP2152308A1 (en) 2007-05-29 2010-02-17 Novartis Ag New indications for anti- il-i-beta therapy
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
AU2008339985C1 (en) 2007-12-21 2012-12-20 Novartis Ag Mammalian expression vector
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
ES2413379T3 (en) 2008-08-28 2013-07-16 Novartis Ag Presentation on the cell surface of polypeptide isoforms by ultrasound codon termination
MX2011009025A (en) * 2009-02-27 2011-09-28 Novartis Ag Expression vector system comprising two selection markers.
ES2440321T3 (en) 2009-02-27 2014-01-28 Novartis Ag Methods to select eukaryotic cells that express a heterologous protein
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
MX353144B (en) 2010-04-20 2017-12-20 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof.
ES2537207T3 (en) 2010-08-16 2015-06-03 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
TWI622597B (en) 2011-03-28 2018-05-01 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
AU2012328322A1 (en) 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
EP2794905B1 (en) * 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
JOP20200308A1 (en) * 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules
WO2014052072A1 (en) 2012-09-26 2014-04-03 3M Innovative Properties Company Coatable composition, soil-resistant composition, soil-resistant articles, and methods of making the same
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
MX2015010843A (en) 2013-02-26 2016-04-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules.
AU2014232501C1 (en) 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
EP2968590B1 (en) 2013-03-15 2018-09-05 Novartis AG Antibody drug conjugates
JP6449229B2 (en) * 2013-03-15 2019-01-09 アッヴィ・バイオセラピューティクス・インコーポレイテッド FC variant
PL3083677T3 (en) 2013-12-20 2020-03-31 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
KR102288857B1 (en) 2013-12-20 2021-08-11 노파르티스 아게 Novel eukaryotic cells and methods for recombinantly expressing a product of interest
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
JP2017536830A (en) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and CD38
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
KR102479084B1 (en) 2015-03-05 2022-12-16 씽크 써지컬, 인크. Methods for Positioning and Tracking the Tool Axis
AU2016262368B2 (en) 2015-05-08 2019-05-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
CN116396393A (en) * 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 Antigen binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
EP3515936A1 (en) * 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
EA201892312A1 (en) * 2017-03-17 2019-04-30 Санофи TRISPECIFIC AND / OR TRIVALENT BINDING PROTEINS
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES

Also Published As

Publication number Publication date
PE20200384A1 (en) 2020-02-24
KR20220167340A (en) 2022-12-20
AU2021206810A1 (en) 2021-08-12
AU2018284303B2 (en) 2021-04-22
IL271179A (en) 2020-01-30
JOP20190283B1 (en) 2023-09-17
TW201906864A (en) 2019-02-16
MA49394A (en) 2020-04-22
AR112419A1 (en) 2019-10-30
MX2019015021A (en) 2020-02-24
CL2019003613A1 (en) 2020-07-03
JOP20190283A1 (en) 2019-12-05
US11987644B2 (en) 2024-05-21
UY37758A (en) 2019-01-31
US20200308309A1 (en) 2020-10-01
JP2022116038A (en) 2022-08-09
CU20190100A7 (en) 2020-11-30
ECSP19087580A (en) 2019-12-27
RU2019140335A (en) 2021-07-13
JP2020524991A (en) 2020-08-27
US20190002589A1 (en) 2019-01-03
KR20200005746A (en) 2020-01-16
RU2019140335A3 (en) 2021-10-04
TWI826377B (en) 2023-12-21
WO2018229612A1 (en) 2018-12-20
KR102633368B1 (en) 2024-02-06
JP7106234B2 (en) 2022-07-26
CR20190558A (en) 2020-01-28
EP3638692A1 (en) 2020-04-22
EA201992670A1 (en) 2020-07-08
CA3061097A1 (en) 2018-12-20
BR112019025904A2 (en) 2020-06-30
CN110730788A (en) 2020-01-24
ZA201906757B (en) 2023-03-29
AU2018284303A1 (en) 2019-11-07
CO2019013838A2 (en) 2020-05-29

Similar Documents

Publication Publication Date Title
IL271179A (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
IL273937A (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
IL279053A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use
HK1258304A1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
HK1250513A1 (en) Anti-ox40 antibodies and methods of use thereof
IL268658A (en) Anti-tau antibodies and methods of use thereof
HUE062436T2 (en) Anti-trem2 antibodies and methods of use thereof
EP3383914A4 (en) Anti-ox40 antibodies and methods of use thereof
HK1251969A1 (en) Anti-her2 antibodies and methods of use
HK1259251A1 (en) Humanized anti-c1s antibodies and methods of use thereof
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
HK1251582A1 (en) Humanized anti-tau(ps422) antibodies and methods of use
IL271346A (en) Bispecific antibodies and methods of making and using thereof
IL258515A (en) Methods of treatment using anti-il-17a/f antibodies
EP3242895A4 (en) A novel anti-egfr monoclonal antibody, method of making, and use thereof
ZA202002144B (en) Antibodies and methods of use
IL273538A (en) Anti-trkb monoclonal antibodies and methods of use
ZA201901120B (en) Crystal and salt of nitroimidazole, and manufacturing method thereof